MedTrace Logo

Lucentis KAV Study

NCT01570608 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2012-04-04

No results posted yet for this study

Summary

Ranibizumab has been proven to be effective in large multicentre studies. However, the injections have to be repeated monthly. A combined therapy with the established photodynamic therapy might even be more effective, less intravitreal injections might be necessary due to a synergistic effect.

The study will be conducted to explore whether intravitreal ranibizumab in monotherapy or in combination with verteporfin photodynamic therapy under a new time regime is an effective, safe and convenient treatment for patients with subfoveal Choroidal Neovascularisation (CNV) secondary to Age-Related Macular Degeneration (AMD).

Conditions

  • Age Related Macular Degeneration

Interventions

DRUG

Ranibizumab

intravitreal injection 3 monthly injections thereafter as needed

DRUG

Verteporfin

Verteporfin photodynamic therapy standard fluence

Sponsors & Collaborators

  • The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery

    lead OTHER

Principal Investigators

  • Ilse Krebs, MD · Ludwig Boltzmann Institute for retinology and biomicroscopic Lasersurgery

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01570608 on ClinicalTrials.gov